Publication
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerBreast Inflammatory Carcinomacivic_curation1.00
- drugBevacizumabcivic_curation1.00
- geneMMP2civic_curation1.00
- geneMMP9civic_curation1.00
- variantMMP2 SERUM LEVELScivic_curation1.00
- variantMMP9 SERUM LEVELScivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26921265
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MMP2 SERUM LEVELS1 | ||||||||
| Bevacizumab | Breast Inflammatory CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1156MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Hig… (full text at CIViC) PMID 26921265 · Tabouret et al., 2016 · Open in CIViC | civic |
| MMP9 SERUM LEVELS1 | ||||||||
| Bevacizumab | Breast Inflammatory CarcinomaALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID1157MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low… (full text at CIViC) PMID 26921265 · Tabouret et al., 2016 · Open in CIViC | civic |